XML 40 R28.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Revenue, Loss and Significant Expenses
The following table is a summary of segment revenue, loss and our significant expenses (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2025202420252024
Collaboration revenue$22,263 $10,971 $50,034 $18,150 
Operating expenses:
External R&D
Rosnilimab15,614 12,926 30,639 22,965 
ANB0333,925 2,982 7,729 5,645 
ANB1012,040 544 3,521 944 
ANB032108 7,584 3,644 12,451 
Imsidolimab(967)1,867 (1,156)6,363 
Preclinical and other unallocated costs4,456 4,693 8,388 8,037 
Total External R&D(1)
25,176 30,596 52,765 56,405 
Total Internal R&D(2)
12,648 11,401 26,239 22,634 
Total R&D37,824 41,997 79,004 79,039 
External G&A(3)
2,436 2,330 7,976 4,451 
Internal G&A(2)
8,173 6,965 16,763 17,182 
Total G&A10,609 9,295 24,739 21,633 
Total operating expenses48,433 51,292 103,743 100,672 
Loss from operations(26,170)(40,321)(53,709)(82,522)
Interest income3,654 4,623 8,067 9,207 
Non-cash interest expense(19,606)(10,953)(37,667)(17,270)
Other income (expense), net3,531 — 5,433 (2)
Total other expense, net
(12,421)(6,330)(24,167)(8,065)
Loss before income taxes(38,591)(46,651)(77,876)(90,587)
Provision for income taxes
(39)(9)(83)(9)
Segment net loss$(38,630)$(46,660)$(77,959)$(90,596)
(1)     External R&D consists of costs associated with our research and development activities, including drug discovery efforts, preclinical and clinical development of our programs, manufacturing, and allocated facility-related costs.
(2)     Internal R&D and G&A consist of salaries and wages, stock-based compensation, recruiting and other employee benefits.
(3)     External G&A consists of general and administrative expenses including transaction costs, legal services, insurance, professional fees for auditing, tax, and market research, and allocated facility-related costs not otherwise included in research and development expenses.